We are live on ! Find out more
Marshall Wace North America

Marshall Wace North America Portfolio holdings

AUM $23.5B Turnover 51.87%
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+46.46%
3 Year Est. Return
+108.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.1B
AUM Growth
+$1.98B
Cap. Flow
+$1.37B
Cap. Flow %
8.51%
Top 10 Hldgs %
18.52%
Holding
1,899
New
351
Increased
456
Reduced
282
Closed
805
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$260M
2
BABA icon
Alibaba
BABA
+$229M
3
GILD icon
Gilead Sciences
GILD
+$168M
4
BA icon
Boeing
BA
+$151M
5
ABT icon
Abbott
ABT
+$148M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$306M
2
UNH icon
UnitedHealth
UNH
+$244M
3
VMC icon
Vulcan Materials
VMC
+$146M
4
PEP icon
PepsiCo
PEP
+$98.4M
5
ELV icon
Elevance Health
ELV
+$96.5M

Sector Composition

Rank Sector Weight
1 Healthcare 27.76%
2 Technology 16.21%
3 Consumer Discretionary 13.94%
4 Industrials 11.18%
5 Communication Services 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BSX icon
1
Boston Scientific
BSX
$64B
$363M 2.25%
8,435,415
-567,255
-6% -$21.8M
2017 Q1
9 quarters
ZTS icon
2
Zoetis
ZTS
$32.4B
$344M 2.13%
3,027,988
-751,782
-20% -$78.7M
2013 Q2
24 quarters
META icon
3
Meta Platforms (Facebook)
META
$1.88T
$323M 2%
1,671,746
+1,424,922
+577% +$260M
2013 Q3
23 quarters
FIS icon
4
Fidelity National Information Services
FIS
$18.6B
$309M 1.92%
2,515,607
+741,411
+42% +$87.1M
2018 Q4
2 quarters
AMZN icon
5
Amazon
AMZN
$2.75T
$299M 1.86%
3,160,680
+165,840
+6% +$15.4M
2013 Q3
23 quarters
BA icon
6
Boeing
BA
$149B
$289M 1.79%
793,577
+413,478
+109% +$151M
2017 Q1
9 quarters
DHR icon
7
Danaher
DHR
$163B
$288M 1.79%
2,276,611
-109,603
-5% -$13M
2013 Q4
22 quarters
SEE icon
8
DELISTED
Sealed Air
SEE
$273M 1.69%
6,380,988
+237,126
+4% +$10.4M
2017 Q1
9 quarters
MRK icon
9
Merck
MRK
$358B
$253M 1.57%
3,163,473
+299,018
+10% +$22.9M
2017 Q1
9 quarters
ADBE icon
10
Adobe
ADBE
$97.9B
$244M 1.51%
827,114
+84,772
+11% +$23.5M
2013 Q3
23 quarters
MSFT icon
11
Microsoft
MSFT
$4.01T
$241M 1.49%
1,796,863
+244,360
+16% +$31M
2017 Q1
9 quarters
GILD icon
12
Gilead Sciences
GILD
$195B
$231M 1.43%
3,418,196
+2,559,972
+298% +$168M
2018 Q3
3 quarters
BABA icon
13
Alibaba
BABA
$276B
$227M 1.41%
1,337,515
+1,326,579
+12,130% +$229M
2017 Q2
8 quarters
BERY icon
14
DELISTED
Berry Global Group, Inc.
BERY
$226M 1.4%
4,684,850
+850,044
+22% +$41M
2013 Q4
22 quarters
USFD icon
15
US Foods
USFD
$22B
$204M 1.27%
5,704,112
+268,974
+5% +$9.77M
2017 Q4
6 quarters
DIS icon
16
Walt Disney
DIS
$191B
$198M 1.23%
1,419,786
+747,247
+111% +$99.1M
2018 Q4
2 quarters
IDXX icon
17
Idexx Laboratories
IDXX
$43.1B
$192M 1.19%
698,227
+294,186
+73% +$72.5M
2017 Q3
7 quarters
DGX icon
18
Quest Diagnostics
DGX
$26.4B
$181M 1.13%
1,780,582
+448,332
+34% +$43.1M
2017 Q1
9 quarters
PTC icon
19
PTC
PTC
$21B
$179M 1.11%
1,995,589
+530,204
+36% +$47.5M
2017 Q1
9 quarters
SPGI icon
20
S&P Global
SPGI
$125B
$177M 1.1%
776,583
+22,464
+3% +$4.91M
2017 Q1
9 quarters
EA icon
21
DELISTED
Electronic Arts
EA
$164M 1.02%
1,623,809
+360,208
+29% +$34.3M
2017 Q2
8 quarters
VRTX icon
22
Vertex Pharmaceuticals
VRTX
$129B
$162M 1.01%
884,990
+92,983
+12% +$16.3M
2017 Q1
9 quarters
TFX icon
23
Teleflex
TFX
$5.43B
$159M 0.99%
479,934
-14,848
-3% -$4.48M
2017 Q1
9 quarters
ABT icon
24
Abbott
ABT
$181B
$158M 0.98%
+1,884,363
New +$148M
2019 Q2
0 quarters
HUM icon
25
Humana
HUM
$51.9B
$142M 0.88%
536,275
+528,637
+6,921% +$134M
2017 Q1
9 quarters
1
2 3 4 5

Similar funds

TPG Group Holdings (SBS) Advisors
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PFM Asset Management
PFM Asset Management Harrisburg, Pennsylvania $5.36B AUM 21.04% 1-Year Est. Return
Homrich & Berg
Homrich & Berg Atlanta, Georgia $4.47B AUM 22.61% 1-Year Est. Return
Marshall Wace Asia
Marshall Wace Asia Central, Hong Kong $4.23B AUM 69.9% 1-Year Est. Return
36 South Capital Advisors
36 South Capital Advisors London, United Kingdom $3.76B AUM
H&F Corporate Investors VII
H&F Corporate Investors VII San Francisco, California $3.61B AUM 26.49% 1-Year Est. Return
Deer VIII & Co
Deer VIII & Co Larchmont, New York $3.56B AUM
NAM
NorthCoast Asset Management Greenwich, Connecticut $2.74B AUM 25.44% 1-Year Est. Return

Marshall Wace North America's Q2 2019 Portfolio in Review

As of Q2 2019, Marshall Wace North America held 1,899 positions worth $16.1B, up 14% from $14.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Marshall Wace North America deployed $1.37B of net new capital in Q2 2019, opening 351 new positions and adding to 456 existing holdings. Its largest new stake was Abbott: 1,884,363 shares worth $158M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Pfizer, an estimated $306M trimmed.

  • Marshall Wace North America's largest Q2 2019 buy was Abbott: 1,884,363 shares worth $158M.
  • Marshall Wace North America added most to Meta Platforms (Facebook) in Q2 2019, an estimated $260M increase.
  • Marshall Wace North America's biggest Q2 2019 reduction was Pfizer, cutting an estimated $306M.
  • Marshall Wace North America fully exited UnitedHealth in Q2 2019, selling an estimated $244M.
  • Marshall Wace North America's ten largest holdings make up 19% of its $16.1B portfolio in Q2 2019.
  • Marshall Wace North America opened 351 new positions and closed 805 in Q2 2019.
  • Marshall Wace North America's portfolio value rose 14% quarter-over-quarter to $16.1B.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.